On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, ...

The European Commission (“EC”) granted marketing approval to AbbVie’s Rinvoq for treating giant cell arteritis (“GCA”), an ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks ...

The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus ...

In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered Imdelltra achieved a statistically ...

Bangalore: AstraZeneca Pharma India Limited has surrendered its marketing authorisation for Olaparib film-coated tablets ...

a phase 3 trial comparing tarlatamab in combination with durvalumab (Imfinzi; AstraZeneca) to durvalumab alone as first-line maintenance therapy in extensive-stage SCLC, and a phase 3 placebo ...

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.